Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

ClinicalTrials.gov ID: NCT06773936

Public ClinicalTrials.gov record NCT06773936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"

Study identification

NCT ID: NCT06773936
Recruitment status: Enrolling by invitation
Study type: Interventional
Phase: Phase 2
Lead sponsor: SWOG Cancer Research Network; Network
Enrollment: 55 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 60 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 13, 2026 (Actual)
Primary completion: May 2029 (Estimated)
Completion: Jul 2033 (Estimated)
Last update posted: Oct 5, 2026

2026 – 2033

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Banner University Medical Center - Tucson	Tucson	Arizona	85719	—
University of Arizona Cancer Center - North Campus	Tucson	Arizona	85719	—
UC Irvine Medical Center	Orange	California	92868	—
Henry Ford Hospital	Detroit	Michigan	48202	—
Nebraska Medicine-Bellevue	Bellevue	Nebraska	68123	—
Nebraska Medicine-Village Pointe	Omaha	Nebraska	68118	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
University of New Mexico Cancer Center	Albuquerque	New Mexico	87102	—
Northwell Health/Center for Advanced Medicine	Lake Success	New York	11042	—
University of Rochester Medical Center	Rochester	New York	14642	—
Duke University Medical Center	Durham	North Carolina	27710	—
University of Cincinnati Cancer Ctr-UC Medical Ctr	Cincinnati	Ohio	45267	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	—
Rhode Island Hospital	Providence	Rhode Island	02903	—
Baptist Memorial Health Care	Memphis	Tennessee	38120	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06773936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 5, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06773936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →